ATE294817T1 - Concatamere immunadhäsion - Google Patents

Concatamere immunadhäsion

Info

Publication number
ATE294817T1
ATE294817T1 AT02753273T AT02753273T ATE294817T1 AT E294817 T1 ATE294817 T1 AT E294817T1 AT 02753273 T AT02753273 T AT 02753273T AT 02753273 T AT02753273 T AT 02753273T AT E294817 T1 ATE294817 T1 AT E294817T1
Authority
AT
Austria
Prior art keywords
proteins
soluble
dimeric
terminus
host cells
Prior art date
Application number
AT02753273T
Other languages
English (en)
Inventor
Yong-Hoon Chung
Ji-Woong Han
Hye-Ja Lee
Eun-Yong Choi
Jin-Mi Kim
Original Assignee
Medexgen Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medexgen Co Ltd filed Critical Medexgen Co Ltd
Application granted granted Critical
Publication of ATE294817T1 publication Critical patent/ATE294817T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70507—CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Dental Preparations (AREA)
AT02753273T 2001-07-26 2002-07-26 Concatamere immunadhäsion ATE294817T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2001-0045028A KR100453877B1 (ko) 2001-07-26 2001-07-26 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
PCT/KR2002/001427 WO2003010202A1 (en) 2001-07-26 2002-07-26 Concatameric immunoadhesion

Publications (1)

Publication Number Publication Date
ATE294817T1 true ATE294817T1 (de) 2005-05-15

Family

ID=36638258

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02753273T ATE294817T1 (de) 2001-07-26 2002-07-26 Concatamere immunadhäsion

Country Status (12)

Country Link
US (3) US7229962B2 (de)
EP (1) EP1362062B1 (de)
JP (1) JP4288159B2 (de)
KR (1) KR100453877B1 (de)
CN (1) CN1293098C (de)
AT (1) ATE294817T1 (de)
AU (1) AU2002313952B2 (de)
CA (1) CA2429384C (de)
DE (1) DE60203996T2 (de)
ES (1) ES2239242T3 (de)
HK (1) HK1062305A1 (de)
WO (1) WO2003010202A1 (de)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071740B2 (en) * 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US6838452B2 (en) * 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
WO2004099231A2 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
EP1436313B1 (de) 2001-10-19 2010-09-22 Vascular Biogenics Ltd. Polynukleotidkonstrukte, pharmazeutische zusammensetzungen und verfahren zur gezielten herunterregulierung von angiogenese und zur krebstherapie
WO2003068802A2 (en) 2002-02-11 2003-08-21 Zymogenetics, Inc. Materials and methods for preparing dimeric growth factors
MXPA04012496A (es) 2002-06-21 2005-09-12 Novo Nordisk Healthcare Ag Glicoformos del factor vii pegilados.
KR100418329B1 (ko) * 2002-07-26 2004-02-14 메덱스젠 주식회사 직렬 연쇄체를 갖는 면역접합체
BRPI0408358A (pt) 2003-03-14 2006-03-21 Neose Technologies Inc polìmeros hidrossolúveis ramificados e seus conjugados
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
AU2004240553A1 (en) 2003-05-09 2004-12-02 Neose Technologies, Inc. Compositions and methods for the preparation of human growth hormone glycosylation mutants
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
EP1694351A2 (de) * 2003-12-03 2006-08-30 Neose Technologies, Inc. Glycopegyliertes follikel-stimulierendes hormon
CA2552892C (en) 2004-01-08 2014-08-05 Neose Technologies, Inc. O-linked glycosylation of peptides
KR20050082389A (ko) * 2004-02-18 2005-08-23 메덱스젠 주식회사 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물
CA2558811A1 (en) 2004-03-08 2005-09-22 Zymogenetics, Inc. Dimeric fusion proteins and materials and methods for producing them
KR100545720B1 (ko) * 2004-05-31 2006-01-24 메덱스젠 주식회사 당화된 면역글로불린 및 이를 포함하는 면역접합체
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
WO2006020372A2 (en) * 2004-07-23 2006-02-23 Neose Technologies, Inc. Enzymatic modification of glycopeptides
CA2574777C (en) 2004-07-23 2015-09-01 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
EP1781684A4 (de) * 2004-08-25 2008-05-21 Amprotein Corp Neues chimäres polypeptid und dessen verwendung
US8268967B2 (en) 2004-09-10 2012-09-18 Novo Nordisk A/S Glycopegylated interferon α
EP1814573B1 (de) 2004-10-29 2016-03-09 ratiopharm GmbH Remodellierung und glykopegylierung von fibroblasten-wachstumsfaktor (fgf)
ES2449195T3 (es) 2005-01-10 2014-03-18 Ratiopharm Gmbh Factor estimulante de colonias de granulocitos glicopegilado
EP1871795A4 (de) 2005-04-08 2010-03-31 Biogenerix Ag Zusammensetzungen und verfahren zur herstellung von glycosylierungsmutanten eines proteaseresistenten menschlichen wachstumshormons
ES2333358T3 (es) * 2005-04-15 2010-02-19 Rappaport Family Institute For Research In The Medical Sciences Moleculas y metodos de uso de las mismas para el tratamiento de enfermedades asociadas con mcp-1/ccr2.
JP5224707B2 (ja) * 2005-04-28 2013-07-03 持田製薬株式会社 抗血小板膜糖蛋白質ｖｉモノクローナル抗体
WO2006117910A1 (ja) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
US20110003744A1 (en) * 2005-05-25 2011-01-06 Novo Nordisk A/S Glycopegylated Erythropoietin Formulations
US20080255026A1 (en) 2005-05-25 2008-10-16 Glycopegylated Factor 1X Glycopegylated Factor Ix
CA2616912A1 (en) * 2005-07-29 2007-02-08 Laboratoires Serono S.A. Use of the globular domain of acrp30 for the preparation of a medicament for the prevention and/or treatment of thrombosis-related diseases
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
WO2007056812A1 (en) * 2005-11-16 2007-05-24 Apollo Life Sciences Limited A molecule and chimeric molecules thereof
WO2007059574A1 (en) * 2005-11-23 2007-05-31 Apollo Life Sciences Limited A molecule and chimeric molecules thereof
CN103432568A (zh) 2005-11-23 2013-12-11 阿塞勒隆制药公司 Activin-ActRIIa拮抗剂及其促进骨骼生长的应用
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8354109B2 (en) 2005-12-13 2013-01-15 Suppremol Gmbh Multimeric Fc receptor polypeptides
US8216996B2 (en) 2006-03-03 2012-07-10 Ono Pharmaceutical Co., Ltd. Multimer of extracellular domain of cell surface functional molecule
PL1999152T3 (pl) * 2006-03-27 2013-05-31 Medimmune Ltd Element wiążący receptor GM-CSF
WO2007147901A1 (en) * 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
ATE555383T1 (de) * 2006-06-22 2012-05-15 Novo Nordisk As Lösliche heterodimere rezeptoren und ihre verwendung
CN101516388B (zh) 2006-07-21 2012-10-31 诺和诺德公司 通过o-联糖基化序列的肽的糖基化
WO2008057683A2 (en) 2006-10-03 2008-05-15 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
BRPI0721078A2 (pt) * 2006-12-13 2014-10-07 Suppremol Gmbh POLIPEPTÍDEOS DE RECEPTORES Fc MULTIMÉRICOS INCLUINDO UM DOMÍNIO Fc MODIFICADO
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
MX2009008222A (es) 2007-02-01 2009-10-12 Acceleron Pharma Inc Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
TW202021980A (zh) 2007-02-02 2020-06-16 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
KR20200054317A (ko) 2007-02-09 2020-05-19 악셀레론 파마 인코포레이티드 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도
KR20100016160A (ko) 2007-04-03 2010-02-12 바이오제너릭스 에이지 글리코페길화 ｇ―ｃｓｆ를 이용하는 치료 방법
ES2565834T3 (es) 2007-06-01 2016-04-07 University Of Maryland, Baltimore Agentes de unión a receptor de Fc de región constante de inmunoglobulina
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
US7968811B2 (en) * 2007-06-29 2011-06-28 Harley-Davidson Motor Company Group, Inc. Integrated ignition and key switch
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
CN103877564A (zh) 2007-09-18 2014-06-25 阿塞勒隆制药公司 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途
CN102037004A (zh) * 2008-01-08 2011-04-27 生物种属学股份公司 使用寡糖基转移酶的多肽的糖缀合
ES2476690T3 (es) 2008-02-27 2014-07-15 Novo Nordisk A/S Moléculas conjugadas del Factor VIII
TW201919685A (zh) 2008-08-14 2019-06-01 美商艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
CN101747440B (zh) * 2008-12-18 2014-05-07 嘉和生物药业有限公司 一种TNFR-Fc融合蛋白及其用途
CA2749544A1 (en) 2009-01-13 2010-07-22 Acceleron Pharma Inc. Methods for increasing adiponectin
CA2764890A1 (en) 2009-06-08 2010-12-16 Acceleron Pharma Inc. Methods for increasing thermogenic adipocytes
AU2010263182B2 (en) 2009-06-12 2016-05-12 Acceleron Pharma Inc. Truncated ActRIIB-Fc fusion proteins
US8710016B2 (en) 2009-11-17 2014-04-29 Acceleron Pharma, Inc. ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
BR112012013330A2 (pt) * 2009-12-02 2017-03-28 Acceleron Pharma Inc composições e métodos para aumentar meia vida do soro de proteínas de fusão fc
EP2521777B1 (de) * 2010-01-05 2016-12-28 Vascular Biogenics Ltd. Zusammensetzungen und verfahren zur behandlung von glioblastomen (gbm)
CN106432474A (zh) 2010-03-12 2017-02-22 艾伯维生物医疗股份有限公司 Ctla4蛋白和其用途
MX368531B (es) 2010-07-28 2019-10-07 Gliknik Inc Proteinas de fusion de fragmentos de proteinas humanas naturales para crear composiciones de fc de inmunoglobulinas multimerizadas ordenadamente.
WO2012064771A1 (en) 2010-11-08 2012-05-18 Acceleron Pharma, Inc. Actriia binding agents and uses thereof
EP2718328A4 (de) * 2011-06-08 2014-12-24 Acceleron Pharma Inc Zusammensetzungen und verfahren zur erhöhung der halbwertszeit von serum
KR102177252B1 (ko) 2012-04-23 2020-11-10 가부시키가이샤 에스 앤드 케이 바이오파마 락토페린 융합 단백질 및 그의 제조방법
KR102279522B1 (ko) 2012-11-02 2021-07-19 셀진 코포레이션 골 및 다른 장애를 치료하기 위한 액티빈-actrii 길항제 및 용도
CN104231086B (zh) * 2013-08-27 2019-12-13 北京韩美药品有限公司 双功能融合蛋白及其制备方法和用途
JP6851200B2 (ja) 2014-03-05 2021-03-31 ユーシービー バイオファルマ エスアールエル 多量体Ｆｃタンパク質
WO2015158867A1 (en) * 2014-04-16 2015-10-22 Ucb Biopharma Sprl Multimeric fc proteins
TN2016000553A1 (en) 2014-06-13 2018-04-04 Acceleron Pharma Inc Methods and compositions for treating ulcers
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
RS64214B1 (sr) 2014-12-03 2023-06-30 Celgene Corp Antagonisti aktivin-actrii i njihova primena u lečenju mijelodisplastičnog sindroma
DK3283508T3 (en) 2015-04-17 2021-05-31 Alpine Immune Sciences Inc Immunomodulatory Proteins with Tunable Affinities
EP3464347B1 (de) 2016-06-07 2023-05-31 Gliknik Inc. Cystein-optimierte stradomere
JP7142915B2 (ja) 2016-10-28 2022-09-28 株式会社Ｓ＆Ｋバイオファーマ ラクトフェリン／アルブミン融合タンパク質及びその製造方法
CN110022898B (zh) 2016-12-09 2023-07-04 格利克尼克股份有限公司 用多价Fc化合物治疗炎性疾病的方法
US11155574B2 (en) 2016-12-09 2021-10-26 Gliknik Inc. Manufacturing optimization of GL-2045, a multimerizing stradomer
CN111372600A (zh) * 2017-03-24 2020-07-03 奥菲斯生物科学公司 治疗自身免疫性疾病的PantId
EP3612555A4 (de) 2017-04-21 2020-12-30 Kindred Biosciences, Inc. Il4/il13-rezeptormolekül zur verwendung in der veterinärmedizin
CA3077509A1 (en) 2017-10-10 2019-04-18 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
WO2020086886A1 (en) * 2018-10-25 2020-04-30 Kindred Biosciences, Inc. Il4/il13 receptor molecule for veterinary use
AU2020407233A1 (en) 2019-12-20 2022-08-18 Regeneron Pharmaceuticals, Inc. Novel IL2 agonists and methods of use thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US53539A (en) * 1866-03-27 Improvement in revolving fire-arms
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US5521288A (en) 1990-03-26 1996-05-28 Bristol-Myers Squibb Company CD28IG fusion protein
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US7253264B1 (en) 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
ES2120949T4 (es) 1990-06-28 2011-12-29 Sanofi-Aventis Deutschland Gmbh 50% Proteinas de fusión con porciones de inmunoglobulinas, su preparación y empleo.
WO1992016221A1 (en) 1991-03-15 1992-10-01 Synergen, Inc. Pegylation of polypeptides
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
DE69226871T3 (de) 1991-06-27 2009-09-24 Bristol-Myers Squibb Co. CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US6090914A (en) 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
US5861151A (en) 1991-12-20 1999-01-19 Bristol-Myers Squibb Co Soluble fusion molecules with binding specificity for cell adhesion molecules
US6100383A (en) 1992-01-27 2000-08-08 Icos Corporation Fusion proteins comprising ICAM-R polypeptides and immunoglobulin constant regions
JPH07505767A (ja) 1992-02-06 1995-06-29 シェリング・コーポレーション ヒトインターロイキン−５に対するヒト化モノクローナル抗体の設計，クローン化および発現
DE4322330A1 (de) 1992-08-31 1994-03-03 Behringwerke Ag Verwendung des IL-4-Rezeptors zur Therapie, Prophylaxe und Diagnose von allergischen, viralen, parasitären und bakteriellen Erkrankungen sowie von Pilzinfektionen
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
CA2123593C (en) 1992-09-15 2000-03-14 Craig A. Smith Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
US5470952A (en) 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
WO1996002576A1 (fr) 1994-07-13 1996-02-01 Chugai Seiyaku Kabushiki Kaisha Anticorps humain reconstitue contre l'interleukine-8 humaine
PE64396A1 (es) 1995-01-23 1997-01-28 Hoffmann La Roche Proteina accesoria del receptor de la interleucina 1
WO1996031229A1 (en) 1995-04-05 1996-10-10 Beth Israel Hospital Association Inhibiting rejection of a graft
CA2223489A1 (en) 1995-07-17 1997-02-06 Joseph A. Fontana Method for treating cancer using ahpn
US6750334B1 (en) * 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US6046310A (en) 1996-03-13 2000-04-04 Protein Design Labs., Inc. FAS ligand fusion proteins and their uses
SE511337C2 (sv) 1996-11-08 1999-09-13 Ericsson Telefon Ab L M Anordning för att skydda sluttransistorerna i en effektförstärkare
KR19980066046A (ko) 1997-01-18 1998-10-15 정용훈 고역가의 CTLA4-Ig 융합단백질
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
IL122818A0 (en) 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
GB9727512D0 (en) 1997-12-31 1998-02-25 Adprotech Plc Fuzzy genes and their application in molecular adjuvants
ATE357459T1 (de) 1998-01-23 2007-04-15 Hoffmann La Roche Antikörper gegen mensliches il-12
US6197294B1 (en) 1998-10-26 2001-03-06 Neurotech S.A. Cell surface molecule-induced macrophage activation
GB0008582D0 (en) * 2000-04-08 2000-05-31 Adprotech Plc DNA immunization vectors
ATE382636T1 (de) * 2000-04-21 2008-01-15 Conaris Res Inst Ag Fusionsproteine, die zwei lösliche gp130 moleküle enthalten
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체

Also Published As

Publication number Publication date
ES2239242T3 (es) 2005-09-16
DE60203996T2 (de) 2006-01-19
JP4288159B2 (ja) 2009-07-01
CA2429384C (en) 2012-08-07
US20100278827A1 (en) 2010-11-04
HK1062305A1 (en) 2004-10-29
EP1362062B1 (de) 2005-05-04
AU2002313952B2 (en) 2003-11-27
WO2003010202A1 (en) 2003-02-06
KR100453877B1 (ko) 2004-10-20
US8372961B2 (en) 2013-02-12
KR20030010189A (ko) 2003-02-05
CN1293098C (zh) 2007-01-03
CN1524092A (zh) 2004-08-25
EP1362062A4 (de) 2004-04-14
US20090011466A1 (en) 2009-01-08
DE60203996D1 (de) 2005-06-09
US20030195338A1 (en) 2003-10-16
CA2429384A1 (en) 2003-02-06
US7670602B2 (en) 2010-03-02
JP2004521655A (ja) 2004-07-22
EP1362062A1 (de) 2003-11-19
US7229962B2 (en) 2007-06-12

Similar Documents

Publication Publication Date Title
ATE294817T1 (de) Concatamere immunadhäsion
ES2342239T3 (es) Expresion y exportacion de angiostatina y de endostatina como inmunofusinas.
RU2008134389A (ru) Рекомбинантные слитые человеческие белки epo-fc с продленным временем полужизни и повышенной эритропоэтической активностью in vivo
TW201336865A (zh) 免疫球蛋白Ｆｃ變體
Stoyan et al. Recombinant soluble human interleukin‐6 receptor: Expression in Escherichia coli, renaturation and purification
SI1873166T1 (sl) IZBOLJĹ ANI sgp 130Fc DIMERJI
RU2011102366A (ru) Фактор viii, фактор виллебранда или их комплексы с удлиненным полупериодом существования in vivo
DE69633175D1 (de) Multimere proteine
CA2899170A1 (en) Compositions and methods of use in treating metabolic disorders
Lethias et al. A model of tenascin-X integration within the collagenous network
CN101124243A (zh) 缀合产物
ZA200408768B (en) Fusions of cytokines and tumor targeting proteins
CN107428842A (zh) 细胞因子融合蛋白
EP3892632A1 (de) Modifiziertes produkt der fc-domäne von antikörpern
Bezouska et al. CD69 antigen of human lymphocytes is a calcium-dependent carbohydrate-binding protein
Tan et al. Engineering the isoelectric point of a renal cell carcinoma targeting antibody greatly enhances scFv solubility
WO2000047740A3 (en) Tnf-related proteins
NO175003B (no) Fusjonsproteiner med eukaryotisk ballastandel, vektor som inneholder et DNA som koder for fusjonsproteinet samt E.coli celle inneholdene vektoren
Katagiri et al. Non‐RGD domains of osteopontin promote cell adhesion without involving αv integrins
KR102357604B1 (ko) 환상 펩티드를 단백질 구조에 제시시키는 초범용법
IE912130A1 (en) Method of treating bladder cancer cells
Addi et al. A highly versatile adaptor protein for the tethering of growth factors to gelatin-based biomaterials
Guo et al. Efficient recovery of the functional IP10-scFv fusion protein from inclusion bodies with an on-column refolding system
CN102725308A (zh) 纤连蛋白:生长因子嵌合物
Pakkanen et al. Selective expression of nonsecreted triple-helical and secreted single-chain recombinant collagen fragments in the yeast Pichia pastoris

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1362062

Country of ref document: EP